Welcome to NRG Oncology!

Welcome to the NRG Oncology Web site! This resource serves to provide current information about NRG Oncology’s exciting research future and the latest updates about plans to support our clinical trial endeavors. We invite you to check back often to learn “what’s new.”

Who We Are

NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

NRG Oncology is proud to be an 
active participant of Cancer Moonshot.

Cancer Moonshot - Blue Ribbon Panel Report

10 Transformative Research Recommendations for Achieving the Cancer Moonshot's Ambitious Goal



Learn about the leaders and plans for NRG Oncology's NCORP Research Base.


NRG Oncology
Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103
Contact Us

To receive the NRG Oncology Newsletter and occasional eNews announcements and press releases, please email

What’s New

NEJM releases new Common Rule regarding federal regulations for the ethical conduct of human subject research. Read more

Anti-androgen Therapy in Addition to Radiation Therapy Improves Long-term Survival for Men with Recurrent or Persistent Prostate Cancer. Read more

NRG Oncology Researchers Develop Improved Model to Predict Glioblastoma Patients’ Response to Radiation Temozolomide Chemotherapy. Read more

NRG Oncology Newsletter Volume 1 2017 is now available. Read more

NRG-LU001 Reaches Patient Accrual Goal. Read more

Results of NRG-NSABP B-52 presented by Mothaffar Rimawi, MD at 2016 SABCS. Read more

Terry Mamounas, MD, presented initial results of NRG-NSABP B-42 at 2016 SABCS. Read more

Drs. Bruner and Gillison Elected to National Academy of Medicine. Read the article.

Douglas W. Arthur, MD discusses breast preserving surgery on NRG-RTOG 1014 in an interview with the ASCO Post. Watch the video 

Deborah Watkins Bruner, RN, PhD presented  "Hypofractionated RT Can Reduce Treatment Time by One-third with Comparable QOL for Prostate Cancer Patients" at ASTRO Annual Meeting. View the slides

Bradley R. Prestidge, MD, MS presented "Intermediate Risk Prostate Cancer May be Well Controlled with Brachytherapy Alone" at ASTRO Annual Meeting. View the slides

Intensity Modulated Radiation Therapy Associated with Reduction in Patient Reported Xerostomia in Head and Neck Cancer Patients. Read more

IDH and CIC Mutations Provide Prognostic Information for Grade II and III Gliomas. Read more

The Addition of External Beam Therapy to Brachytherapy Does Not Produce Superior Progression-Free Survival Results for Intermediate Risk Prostate Cancer Patients. Read more

Shortened Radiation Therapy Schedule Effective in Patients with Low-Risk Prostate Cancer. Read more

Intensity Modulated Pelvic Radiation Therapy Reduces Patient Reported Toxicities. Read more

Stereotactic Body Radiation Therapy Found Safe for Medically Inoperable Patients with Non-Small Cell Lung Cancer. Read more

NRG Oncology Newsletter Volume 2 2016 is now available. Read more

Copyright 2017 by NRG Oncology